4 research outputs found
New horizons from novel therapies in malignant pleural mesothelioma
Malignant pleural mesothelioma (MPM) is a relatively rare, but highly lethal cancer of the pleural mesothelial cells. Its pathoge-nesis is integrally linked to asbestos exposure. In spite of recent developments providing a more detailed understanding of the pathogenesis, the outcomes continue to be poor. To date, trimodality therapy involving surgery coupled with chemotherapy and/or radiotherapy remains the standard of therapy. The development of resistance of the tumor cells to radiation and several che-motherapeutic agents poses even greater challenges in the management of this cancer. Ionizing radiation damages cancer cell DNA and aids in therapeutic response, but it also activates cell survival signaling pathways that helps the tumor cells to overcome radiation-induced cytotoxicity. A careful evaluation of the biology involved in mesothelioma with an emphasis on the workings of pro-survival signaling pathways might offer some guidance for treatment options. This review focuses on the existing treatment options for MPM, novel treatment approaches based on recent studies combining the use of inhibitors which target different pro-survival pathways, and radiotherapy to optimize treatment
Nowe perspektywy leczenia z艂o艣liwego mi臋dzyb艂oniaka op艂ucnej
Z艂o艣liwy mi臋dzyb艂oniak op艂ucnej to stosunkowo rzadko wyst臋puj膮ca choroba rozrostowa kom贸rek mezotelialnych op艂ucnej, cechuj膮ca si臋 du偶膮 艣miertelno艣ci膮. Jej patogeneza nieod艂膮cznie wi膮偶e si臋 z ekspozycj膮 na dzia艂anie azbestu. I chocia偶 coraz wi臋cej wiadomo na ten temat, nadal wiele zagadnie艅 dotycz膮cych mechanizmu powstawania i rozwoju z艂o艣liwego mi臋dzyb艂oniaka op艂ucnej pozostaje niejasnych. Terapia tr贸jmodalna, sk艂adaj膮ca si臋 z leczenia chirurgicznego skojarzonego z chemioterapi膮 i/lub radioterapi膮, nadal pozostaje terapi膮 standardow膮. Rozw贸j oporno艣ci kom贸rek guza na radioterapi臋 oraz niekt贸re 艣rodki chemioterapeutyczne bardzo utrudniaj膮 leczenie tego nowotworu. Promieniowanie jonizuj膮ce uszkadza DNA kom贸rek nowotworowych i zwi臋ksza odpowied藕 na leczenie, lecz uaktywnia tak偶e szlaki sygna艂owe prze偶ycia kom贸rki, co pozwala kom贸rkom nowotworowym pokona膰 cytotoksyczno艣膰 wywo艂an膮 promieniowaniem. Uwa偶na ocena mi臋dzyb艂oniaka na poziomie biologicznym, z naciskiem na mechanizmy dzia艂ania szlak贸w sygna艂owych prowadz膮cych kom贸rk臋 na drog臋 prze偶ycia, mo偶e by膰 pomocna przy wyborze opcji terapeutycznej. Niniejsza praca skupia si臋 na dost臋pnych metodach leczenia z艂o艣liwego mi臋dzyb艂oniaka op艂ucnej, nowym podej艣ciu terapeutycznym opartym na najnowszych badaniach, wykorzystuj膮cym inhibitory ukierunkowane na r贸偶ne szlaki sprzyjaj膮ce prze偶yciu i radioterapii stosowanej w celu optymalizacji metod leczenia
New Horizons from Novel Therapies in Malignant Pleural Mesothelioma
Malignant pleural mesothelioma (MPM) is a relatively rare, but highly lethal cancer of the pleural mesothelial cells. Its pathoge-nesis is integrally linked to asbestos exposure. In spite of recent developments providing a more detailed understanding of the pathogenesis, the outcomes continue to be poor. To date, trimodality therapy involving surgery coupled with chemotherapy and/or radiotherapy remains the standard of therapy. The development of resistance of the tumor cells to radiation and several che-motherapeutic agents poses even greater challenges in the management of this cancer. Ionizing radiation damages cancer cell DNA and aids in therapeutic response, but it also activates cell survival signaling pathways that helps the tumor cells to overcome radiation-induced cytotoxicity. A careful evaluation of the biology involved in mesothelioma with an emphasis on the workings of pro-survival signaling pathways might offer some guidance for treatment options. This review focuses on the existing treatment options for MPM, novel treatment approaches based on recent studies combining the use of inhibitors which target different pro-survival pathways, and radiotherapy to optimize treatment
Utilization of radiation therapy and predictors of noncompliance among Syrian refugees in Turkey
Background: Access to cancer care is a problem that continues to plague refugees displaced from their home countries. The turbulent political crisis in Syria, which has led to millions of refugees seeking asylum in Turkey, merits further attention. We aimed to study the rate of utilization of radiation therapy among Syrian refugees with cancer living in Turkey in an attempt to identify the contributing factors predictive of non-compliance with prescribed RT